Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
After Apellis Deal, Biogen Looks to Fill Early-Stage Pipeline
Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals, adding a complement‑inhibition platform to its portfolio. While the deal closes this month, the company emphasized that its growth engine will now hinge on early‑stage development and research rather than late‑stage launches. Executives indicated a continued appetite for strategic deals to bolster the pipeline. The move reflects Biogen’s effort to diversify beyond its traditional neuro‑degeneration assets and address a slowing pipeline of late‑stage candidates.
Brenntag Pharma Unveiled BYPHAR, the New Regulated Biopharma Manufacturing Brand
Brenntag Pharma introduced BYPHAR, a new regulated biopharma manufacturing brand that consolidates high‑quality raw materials, advanced facilities, and value‑added services into a single, compliance‑ready portfolio. The brand groups materials into three tiers—Explore, Enhance, and Excel—covering non‑GMP to LBLE critical grades,...
March 2026 Patent Highlights
The March 2026 Patent Highlights page aggregates the latest drug‑discovery milestones, from 38 first‑time small‑molecule approvals by Europe’s EMA, China’s NMPA and Japan’s PMDA to a deep dive on protein‑structure advances and machine‑learning tools. It spotlights a newly optimized HPK1 inhibitor...
Circio Partners with TraffikGene Project to Advance Non-Viral circVec Delivery
Circio, an Oslo‑based circular RNA company, has partnered with the Universidad de Santiago de Compostela’s TraffikGene project to explore non‑viral delivery of its circVec circular RNA expression vectors. The collaboration merges Circio’s circVec platform with TraffikGene’s peptide amphiphile carrier system...
LFCR Undervalued; Upcoming Site Transfers Could Drive 25% Margins
$LFCR beaten down again on fears of equity issuance, lingering preferred concerns, and general liquidity worries. They have enough liquidity to cover the preferreds. Debt is not a concern as of yet. Meanwhile, the company has reported 5 site transfers in the...
SYRE Jumps to $8B After Breakthrough UC Trial
$SYRE pushing $8 billion cap currently on a major $XBI red day following their open label a4b7 data proving that a4b7 continues to work. Valuation was ~$3B at the start of the year. Must’ve been a massive surprise that their...
Top Cardiology News for April 2026
TCTMD’s Heart Sounds podcast paid tribute to cardiology legend Eugene Braunwald, underscoring his decades‑long influence on clinical practice and research. The episode also curated the team’s top cardiology studies from the past weeks, spanning AI‑driven ECG analysis, a novel SGLT2...
Healthy Workers Are Ditching Company Insurance to Save $1,000 a Month
Rising health‑care premiums are prompting healthy, young workers to abandon employer‑sponsored insurance in favor of cheaper alternatives. A Buffalo nurse and her family saved $970 per month by joining a medical‑cost‑sharing cooperative and enrolling their children in a state child‑health...
FDA Knew of Better Method to Detect COVID Vaccine Safety Signals — But Refused to Use It
Senator Ron Johnson released a report showing that FDA officials during the Biden administration knew a superior empirical Bayesian data‑mining method existed for detecting COVID‑19 vaccine safety signals in VAERS but ordered staff to continue using the older, flawed tool....
Health Care Ranks Equal to Gas in Voter Concerns
Even as gas prices cause real pain for consumers and dominate the news, our new poll finds health care tied with gas as the public's top economic worries. Health care affordability is a big issue for voters this year. https://www.kff.org/public-opinion/kff-health-tracking-poll-health-care-costs-and-the-midterms/
Assisted Death Need of People Whose Life Is Living Hell, Difficulties Are Stupendous Re: Assisted Dying Bill Supporters Vow to...
A physician’s open letter to the BMJ highlights the ethical and legal quagmire surrounding assisted dying for patients in vegetative states and terminal illness. The author raises four core questions: who can request, who decides, what criteria apply, and who...
PFA's Dominance and Other Key Electrophysiology Trends on Display at Heart Rhythm 2026
Pulse‑field ablation (PFA) is emerging as a durable, safer alternative for atrial fibrillation, delivering higher first‑pass isolation rates and fewer repeat procedures. Experts predict a dual‑energy future where PFA and radiofrequency ablation (RFA) are combined to treat thicker tissue and...
Thermo Fisher Scientific Launches Applied Biosystems PowerFlex Thermal Cycler
Thermo Fisher Scientific unveiled the Applied Biosystems PowerFlex Thermal Cycler, a next‑generation PCR instrument that emphasizes speed, precision, and flexibility. The system features a 10.1‑inch touchscreen, AI‑driven Smart Help, and two configuration options—a 96‑well plate and a 3 × 32‑well layout with...
Sleep: The Next Frontier in Health Innovation
We often think of medical interventions as being only about new breakthrough drugs or diagnostics, but our daily behaviors also have a profound impact on health outcomes. And it’s great to see that being increasingly recognized in the healthcare system....
Nanozymes Against Brain Tumors
Researchers at Empa and HOCH Health Ostschweiz are developing biocompatible nanozymes that can be applied directly during brain‑tumor surgery to attack astrocytoma cells. The nanozymes act like enzymes, generating reactive‑oxygen species and activating drug precursors, and they are triggered by...
Muse Headband’s Decade‑Long Evolution Boosts Mindfulness Guidance
About a decade ago, I had a chance to test the first Muse Headband that claimed to measure EEG (essentially brain waves) at home and provide biofeedback while doing meditations. Muse redesigned its device by 2026 and they sent me a...
Biogen Ready to Catch Alzheimer’s Patients Transitioning Off Lilly’s Kisunla
Biogen is positioning its Leqembi therapy to capture Alzheimer’s patients who will finish Eli Lilly’s 18‑month Kisunla regimen and need a maintenance option. Leqembi, approved in January 2023, saw a 74% year‑over‑year sales jump to $168 million in Q1 2026, beating expectations. Biogen is...
The Best Possible Patient Outcome Goes Beyond Prior Authorization
Brian Smith, chief pharmacy officer at Shields Health Solutions, argues that prior authorization alone fails patients who cannot afford prescribed drugs. He emphasizes that true patient care must address financial barriers alongside clinical approval processes. Shields Health is promoting a...
Egg Freezing: Expensive Gamble, Rarely Yielded Returns
Egg freezing costs $10,000 to $20,000 per cycle. Most women need more than one cycle to bank enough eggs. Then you pay $500 to $1,000 a year in storage fees, indefinitely. According to the largest U.S. study to date, only...
Tomorrow's Dual AZN ODAC: Serena-6 AM, Truqap-281
Reminder that the dual $AZN ODAC takes place tomorrow. Camizestrant Serena-6 trial being debated in the morning, then Truqap Capitello-281 in the afternoon. Youtube link -> https://t.co/RDcvhRqVWR
The Trump Team Is Quietly Eliminating U.S. Support for Birth Control Abroad
The Trump administration has stopped spending the $575 million Congress appropriated for international family‑planning, effectively ending U.S. support for birth‑control programs abroad. The cuts have shuttered clinics, fired community health workers like Uganda’s Prossy Muyingo, and created a shortfall that threatens...
Skin Nerve Fibers Slow Melanoma Growth, Challenging Cancer Neuroscience
A twist in cancer neuroscience with many studies showing hijacking of neurons to promote cancer—melanoma growth slowed by nerve fibers in skin https://t.co/9OWEAhJPOb https://t.co/XGSdYYPqk8
Hospitals Wield Outsized Congressional Influence over Health Policy
in my 40 years covering Congress, hospitals have ALWAYS had disproportionate clout compared to other major players in the health care system.
&You Is Reimagining Access to Everyday Healthcare
&you is a digital health platform that merges telehealth consultations, prescription services, and home delivery of treatments into a single, user‑friendly experience. Founder and CEO Emil Eriksen says the service targets stigma‑laden areas such as sexual health, dermatology, and wellness,...
AstraZeneca’s £300m UK Return Shows the Price Britain Paid to Win Back Pharma Money
AstraZeneca is restarting a £300 million (≈$380 million) research investment in the UK after the UK‑US pharmaceutical agreement boosted expected returns. The plan funds the completion of the Rosalind Franklin building in Cambridge and a new digital drug‑development lab, reflecting higher NHS...
Democrats Shy Away From Hospital Criticism Amid Lobby Power
Yesterday's House committee hearing on health care affordability showed in stark terms how averse Democrats are to criticizing #hospitals, a testament to their lobbying power. https://t.co/3P1OKFc3rU via @statnews
Healthcare AI News 4/29/26
Central Maine Healthcare announced the layoff of 38 IT workers as Maine pushes a statewide, Wisconsin‑based electronic health record (EHR) platform. The state is committing public funds to the vendor despite ongoing antitrust scrutiny, mirroring concerns raised by Memorial Sloan...
AI-Driven Layoffs In Healthcare: Navigating Legal Risks and Operational Challenges
Artificial intelligence is accelerating workforce reductions across sectors, and healthcare is feeling the impact. Large employers such as Amazon, UPS and Verizon have announced tens of thousands of AI‑related cuts, while a Utah physician‑owned network and CVS Health have trimmed...
Prior Auth Challenges Mount as Demand Proliferates
Prior authorization (PA) requests are surging, with industry data showing a 22% year‑over‑year increase in volume across U.S. health systems. Clinicians, like Shields Health Solutions’ chief pharmacy officer Brian Smith, acknowledge growing frustration as each PA adds an average 15‑minute...
Inside Servier’s New €200M Venture Fund
Servier has unveiled a new corporate venture fund, committing roughly $216 million to back early‑stage biotech focused on oncology and neurology. The fund, Servier Ventures, will target late pre‑clinical and Series A assets where it can add capital and industrial expertise, especially...
How Disintermediation Is Being Managed in Rx Models
Employers are moving away from traditional, single‑vendor pharmacy benefit managers, with transparent PBM adoption climbing to 31% in 2025 from 12% in 2024. This disintermediation creates multi‑vendor configurations that split claims, rebates, specialty management, and clinical navigation across separate partners....
Rad AI Appoints Chief Operating Officer and First Chief Clinical Officer, Strengthening Operational and Clinical Strategy
Rad AI announced the promotion of David Leonard to chief operating officer and the appointment of Dr. Elizabeth Bergey as its first chief clinical officer. Leonard, formerly head of operations, strategy and investor relations, will oversee global operations and drive...
Re: Overcommercialisation of Dental Practice in England and Decline in Oral Health
In a rapid response to a BMJ article on England’s over‑commercialised dental sector, Russian reviewer Sergei Jargin highlights similar market‑driven pressures and oral‑health inequities in Russia today. He contrasts the current situation with Soviet‑era practices, where children received crude extractions...
AI Cheapens Scans, Boosts Radiologist Demand and Salaries
The Radiologist Paradox "A decade ago, AI was supposed to replace radiologists. Today, radiologists make more than $500,000 per year, and their employment continues to grow, see chart below. Reading scans is a task, not a job, and when the...
Rula State of Mental Health Report 2026: Financial Stress and AI Chatbot Trends in Behavioral Healthcare
Rula’s 2026 State of Mental Health Report, based on a survey of 2,037 U.S. adults, reveals a widening gap between mental‑health awareness and actual service use. Financial stress is the top barrier, with 25% citing cost and half cutting health...
US Firm Implants Brain Device in China, Rare Cooperation
"A US company has tested a brain implant in a Chinese patient in Shanghai, a rare sign of cooperation as the two countries compete to develop the most advanced neurotechnology." https://t.co/4xEs7DZTpk
Candel Therapeutics Announces Commercial Agreement with EVERSANA to Support U.S. Launch of Prostate Cancer Therapy
Candel Therapeutics announced a commercialization agreement with EVERSANA to support the potential U.S. launch of its gene‑therapy candidate aglatimagene besadenovec (CAN‑2409) for intermediate‑ to high‑risk localized prostate cancer. EVERSANA will deliver a full suite of services, including data analytics, medical...
Zócalo Health Finds Growth in Medicaid Managed Care Partnerships
Zócalo Health closed a $15 million Series A round, bringing total capital to $22.75 million, to scale its virtual primary‑care platform for underserved Latino patients. The company has moved beyond its California launch, now serving Medicaid members in California, Texas, Washington and expanding...
AI Model Detects Pre‑Symptom Alzheimer’s Fingerprint
𝐀𝐈 𝐅𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐊𝐞𝐲 𝐭𝐨 𝐏𝐫𝐞-𝐒𝐲𝐦𝐩𝐭𝐨𝐦 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 #FINGERPRINT Introducing #FINGERS7B, the first AI foundation model designed specifically to prevent Alzheimer’s disease via @NeuroscienceNew https://t.co/J7XKdg7drF https://t.co/QQKyverDNZ
Financial Assistance Reform Is Reshaping Revenue Cycle Strategy
In 2026 a wave of state financial‑assistance reforms turns hospital affordability from guidance into enforceable law. Laws such as Maine’s LD 1937 require mandatory income‑based payment plans, pause collections during eligibility review, and impose multilingual disclosures. Similar statutes in Maryland, Oregon,...
Beyond Support Teams: The Strategic Role of Centers of Excellence in Healthcare
Healthcare systems are channeling new technology dollars into Centers of Excellence (COEs) to tackle workforce shortages, regulatory pressure, and EHR fatigue. A COE is positioned as a governance and execution model that aligns technology choices with clinical, financial, and operational...
Chiesi Signs $1.9B Deal to Acquire KalVista and Its Approved Drug
Italian pharmaceutical group Chiesi announced a $1.9 billion cash acquisition of U.S. biotech KalVista Pharmaceuticals, paying $27 per share. KalVista brings an FDA‑approved therapy for a rare disease into Chiesi’s portfolio, bolstering its specialty drug offerings. The deal is part of...
Marriage Cuts Cancer Risk, Especially for Women
🚨New Study: Marriage more protective against cancer for women than men @WSJ: ✔️Cancer rates 68% higher for never-married men But. . . ✔️Cancer rates 83% higher for never-married men https://t.co/eQcmo0pa4B
UnitedHealthcare Survey Finds 62% of Young Adults Face Mental‑Health Challenges
UnitedHealthcare released its fourth annual Young Adult & College Student Behavioral Health Report, showing that 62% of respondents aged 18‑28 reported a mental or behavioral health issue in the past year. The findings underscore persistent strain across education and employment...
AstraZeneca Bullish on $80B Sales Goal After Beating Expectations, Phase 3 Data Wins
AstraZeneca reported first‑quarter sales of $15.3 billion, surpassing the $14.7 billion consensus estimate and delivering 8% constant‑currency growth. The surge was led by oncology products Enhertu and Imfinzi, while the rare‑disease unit contributed $2.4 billion, anchored by Ultomiris. New alliance revenue from the...
SRN‑901 Extends Mouse Lifespan by 33% in Preclinical Trial, Raising Longevity Hopes
SinoGen, Tsinghua University and China National Pharmaceutical announced that the oral anti‑aging candidate SRN‑901 extended median remaining lifespan by 33% in naturally aging mice. The study also cut tumor incidence by 30% and slowed visible aging signs, positioning the drug...
Paradigm Health Teams with FDA and Pharma Giants to Speed Trial Data Review
Paradigm Health announced a partnership with the U.S. Food and Drug Administration, Amgen and AstraZeneca to pilot an integrated technology platform that delivers real‑time trial data to regulators, promising to shrink review cycles from months to days. The model, already...
Chiesi Expands Rare Disease Portfolio, Acquires KalVista for $1.9 Billion
Chiesi Group announced a $1.9 billion cash acquisition of KalVista Pharmaceuticals, its largest deal to date. The purchase adds EKTERLY (sebetralstat), the first oral, on‑demand therapy for hereditary angioedema (HAE), to Chiesi’s rare‑disease pipeline. EKTERLY is already approved in major markets...
Why the GLP-1 Boom Has a Litigation Wave Right Behind It
GLP‑1 receptor agonists such as semaglutide and tirzepatide have surged from diabetes treatment to popular weight‑loss drugs, creating a multi‑billion‑dollar market. Their rapid adoption across physician offices, weight‑loss centers, compounding pharmacies, and online platforms has exposed gaps in patient screening,...
STAT+: Pharmalittle: We’re Reading About the FDA Speeding up Trials, a Supreme Court Hearing on ‘Skinny Labels,’ and More
The FDA announced a pilot program that will review real‑time data from AstraZeneca and Amgen cancer trials using a platform built by Paradigm Health, aiming to speed regulatory feedback. The agency also opened a public comment period on a separate...